We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Imaging Technology May Slash X-Ray Exposure for Liver Cancer Patients

By HospiMedica International staff writers
Posted on 10 Dec 2014
Researchers reported that their evaluation of an interventional X-ray guidance device approved by the US Food and Drug Administration (FDA) in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.

The study’s findings were presented at the 100th annual meeting of the Radiological Society of North America (RSNA) in Chicago (IL, USA) where John Hopkins University (Baltimore, MD, USA) researchers described the findings of a clinical trial of the imaging system AlluraClarity developed by Philips Healthcare (Best, The Netherlands), on 50 patients with liver cancer. More...
Its use reduced radiation exposure up to 80%, compared with exposure from a standard imaging X-ray platform used in IAT, while producing images just as clear as the standard system, according to Jean-Francois Geschwind, MD, a professor in the Russell H. Morgan department of radiology and radiological science in the Johns Hopkins University School of Medicine and its Kimmel Cancer Center.

Dr. Geschwind stated that if further studies continue to affirm his team’s findings, the platform may be especially useful for patients who need repeat therapy; children, who are especially vulnerable to radiation; and physicians who routinely use procedures such as IAT and are exposed to radiation.

During IAT, a physician inserts a thin, flexible tube directly into a blood vessel feeding a tumor, using that pathway to deliver chemotherapy or other drugs. X-ray imaging is used during the procedure to visualize the patient’s blood vessels and to guide both the catheter’s placement and drug delivery. Dr. Geschwind and his colleagues compared the radiation exposure of 25 patients with liver cancer treated with IAT using the AlluraClarity platform to the exposure of 25 additional patients with liver cancer treated with IAT using Philips' previous X-ray imaging platform, called Allura.

Dropping the radiation output on standard X-ray imaging platforms can reduce the exposure, but without special image processing, the amount of image noise increases and physicians are unable to see small structures needed for good treatment, according to Ruediger Schernthaner, MD, a postdoctoral research fellow in vascular and interventional radiology at The Johns Hopkins Hospital. “You can compare this to an image taken with your cell phone in the evening without a flash,” he said.

The AlluraClarity platform uses a series of real-time image processing algorithms to achieve high quality images at a lower radiation power, Dr. Schernthaner reported.

Related Links:

John Hopkins University
Philips Healthcare



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.